AusBiotech committees and advisory group chairs took advantage of the national gathering at AusBiotech 2017 last week to meet and update one another on the work of respective groups.
The chairs represent more than 120 AusBiotech members who volunteer their time to 17 committees, to share information and work on sector issues and develop networking and educational events.
Two new chairs were announced at the meeting: Sarah Griffin to lead the AusMedtech Health Economics Expert Panel (HEEP); and, Paul Carboon to lead the Victorian AusMedtech Committee.
Sarah Griffin has recently been appointed to Chair the AusMedtech HEEP
Sarah is the founder of Medtechnique Consulting and has more than 25 years experience in the medical technology sector, including in health economics, health insurance, health policy and legislation, medical finance, reimbursement systems and government relations. Sarah’s strengths lie in her strategic approach to market access and the creation of effective reimbursement and health economic strategies. She is a registered lobbyist and an expert in preparing complex reimbursement submissions. Since founding Medtechnique in 2013, she has assisted numerous medical technology companies gain market access for innovative technologies.
Sarah has filled senior and international roles with St Jude Medical, MBF and Mercy Health Services in the United States. Sarah received her B.App Sc (Physio) from the University of Sydney and a GradDip in Health Economics and Policy from Monash University. She has served on several committees, including the Trade and Government Committee of the American Chamber of Commerce. She is a current and active member of AusBiotech and MTAA.
Paul Carboon has recently been appointed to Chair the Victorian AusMedtech Committee
Following Ian Reilly’s resignation, Paul Carboon has been appointed to the Chair role.
Paul has over 20 years’ experience in R&D product development, with a significant background in software/electronics systems development. Paul has an extensive and very successful track record in developing ‘green fields’ into world-leading products, deployed into international markets. Paul leads Hydrix business development focus on the growing the medtech ecosystem. Paul works to translate early-stage research from universities and other IP generators, define the projects, find funding, match with channel partners, negotiate IP arrangements, sets up start-ups, then enables systems design, product development, verification, validation, clinical trials into marketing and product reimbursement.